← Leaderboards
Hua E Yu
Beckman Research Institute/City Of Hope
$13,108,796
Attributed
$15,704,270
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,704,270 · 11
By mechanism
R01$13,240,953 · 8
P50$1,421,932 · 1
U54$751,448 · 1
R29$289,937 · 1
Top collaborators
- David K Ann5 shared
- Wendong Huang5 shared
- Richard Jove2 shared
- Ross Okimoto1 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Sophia S. Wang$9,836,949
- Xiuli Wang$2,702,470
- Robert Wi Chen$1,186,185
- Tanya Siddiqi$833,273
- Ryotaro Nakamura$3,182,963
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorNeoplastic CellMalignant NeoplasmsMolecularMediatingCellsLeadCancer TherapySmall MoleculeSignal TransductionPathway InteractionsCell SurvivalOncogenicResistanceIn VivoInhibitor/AntagonistCancer CellGenesImmuneMouse ModelApoptosisNeoplasm MetastasisTranscription FactorInsight
Grant awards (53)
The role of IL-6/STAT3 signaling in CIC-DUX4 fusion sarcoma metastasis and immunosuppression$593,028
R01 · FY2025 · CA · contact PI
Fatty acids and their receptors-mediated tumor metastasis and progression$382,471
R01 · FY2024 · CA · contact PI
Fatty acids and their receptors-mediated tumor metastasis and progression$394,548
R01 · FY2023 · CA · contact PI
Fatty acids and their receptors-mediated tumor metastasis and progression$394,548
R01 · FY2022 · CA · contact PI
Novel nucleotide-based approaches targeting the STAT3 pathway for the treatment of lymphoma$258,100
P50 · FY2022 · CA · contact PI
MiRNAs in hepatocellular carcinoma development and treatment$410,875
R01 · FY2021 · CA
Fatty acids and their receptors-mediated tumor metastasis and progression$402,600
R01 · FY2021 · CA · contact PI
Novel nucleotide-based approaches targeting the STAT3 pathway for the treatment of lymphoma$297,623
P50 · FY2021 · CA · contact PI
MiRNAs in hepatocellular carcinoma development and treatment$410,875
R01 · FY2020 · CA
Fatty acids and their receptors-mediated tumor metastasis and progression$402,600
R01 · FY2020 · CA · contact PI
Novel nucleotide-based approaches targeting the STAT3 pathway for the treatment of lymphoma$252,494
P50 · FY2020 · CA · contact PI
MiRNAs in hepatocellular carcinoma development and treatment$398,548
R01 · FY2019 · CA
Novel nucleotide-based approaches targeting the STAT3 pathway for the treatment of lymphoma$301,237
P50 · FY2019 · CA · contact PI
MiRNAs in hepatocellular carcinoma development and treatment$410,875
R01 · FY2018 · CA
Novel nucleotide-based approaches targeting the STAT3 pathway for the treatment of lymphoma$312,478
P50 · FY2018 · CA · contact PI
MiRNAs in hepatocellular carcinoma development and treatment$410,875
R01 · FY2017 · CA
Role of Stat3 in Tumor Immune Evasion and Immune Suppression$289,553
R01 · FY2015 · CA · contact PI
Targeting S1PR1/JAK2/STAT3 Signaling Axis in EMDR$212,282
U54 · FY2015 · CA · contact PI
Role of Stat3 in Tumor Immune Evasion and Immune Suppression$280,866
R01 · FY2014 · CA · contact PI
Targeting S1PR1/JAK2/STAT3 Signaling Axis in EMDR$196,582
U54 · FY2014 · CA · contact PI
Targeting Stat3 to Improve Immunotherapy$314,070
R01 · FY2013 · CA · contact PI
Role of Stat3 in Tumor Immune Evasion and Immune Suppression$272,180
R01 · FY2013 · CA · contact PI
Targeting S1PR1/JAK2/STAT3 Signaling Axis in EMDR$150,082
U54 · FY2013 · CA · contact PI
Targeting Stat3 to Improve Immunotherapy$334,117
R01 · FY2012 · CA · contact PI
Role of Stat3 in Tumor Immune Evasion and Immune Suppression$289,553
R01 · FY2012 · CA · contact PI
Targeting S1PR1/JAK2/STAT3 Signaling Axis in EMDR$192,502
U54 · FY2012 · CA · contact PI
Targeting Stat3 to Improve Immunotherapy$334,117
R01 · FY2011 · CA · contact PI
Role of Stat3 in Tumor Immune Evasion and Immune Suppression$289,553
R01 · FY2011 · CA · contact PI
Targeting Stat3 to Improve Immunotherapy$344,450
R01 · FY2010 · CA · contact PI
Role of Stat3 in tumor immune evasion and immune suppression$291,277
R01 · FY2010 · CA · contact PI
Role of Stat3 in modulating tumor microenvironnment and angiogenesis$291,276
R01 · FY2010 · CA · contact PI
Targeting Stat3 to Improve Immunotherapy$344,450
R01 · FY2009 · CA · contact PI
Role of Stat3 in tumor immune evasion and immune suppression$291,277
R01 · FY2009 · CA · contact PI
Role of Stat3 in modulating tumor microenvironment and angiogenesis$291,276
R01 · FY2009 · CA · contact PI
Role of Stat3 in tumor immune evasion and immune suppression$291,277
R01 · FY2008 · CA · contact PI
Role of Stat3 in modulating tumor microenvironment and angiogenesis$291,276
R01 · FY2008 · CA · contact PI
Role of Stat3 in tumor immune evasion and immune suppression$291,277
R01 · FY2007 · CA · contact PI
Role of Stat3 in modulating tumor microenvironment and angiogenesis$291,276
R01 · FY2007 · CA · contact PI
Stat3 and anti-VEGF therapy in cancer$285,231
R01 · FY2007 · CA · contact PI
Role of Stat3 in tumor immune evasion and immune suppression$299,975
R01 · FY2006 · CA · contact PI
Role of Stat3 in modulating tumor microenvironnment and angiogenesis$299,975
R01 · FY2006 · CA · contact PI
Stat3 and anti-VEGF therapy in cancer$293,751
R01 · FY2006 · CA · contact PI
Immune Responses in Cancer Therapy$260,260
R01 · FY2005 · CA
Stat3 and anti-VEGF therapy in cancer$156,457
R01 · FY2005 · CA
Stat3 and anti-VEGF therapy in cancer$140,568
R01 · FY2005 · CA
Stat3 and anti-VEGF therapy in cancer$290,140
R01 · FY2004 · CA
Immune Responses in Cancer Therapy$223,300
R01 · FY2004 · CA
Stat3 and anti-VEGF therapy in cancer$286,432
R01 · FY2003 · CA
Immune Responses in Cancer Therapy$223,300
R01 · FY2003 · CA
Immune Responses in Cancer Therapy$223,300
R01 · FY2002 · CA
Immune Responses in Cancer Therapy$223,300
R01 · FY2001 · CA
CYTOKINES AS CANCER IMMUNOTHERAPEUTICS$148,417
R29 · FY2001 · CA
CYTOKINES AS CANCER IMMUNOTHERAPEUTICS$141,520
R29 · FY2000 · CA